Cargando…
Vitamin E succinate exerts anti-tumour effects on human cervical cancer cells via the CD47-SIRPɑ pathway both in vivo and in vitro
Vitamin E succinate (RRR-a-tocopheryl succinate, VES) acts as a potent agent for cancer therapy and has no toxic and side effects on normal tissue cells. However, the mechanism by which VES mediates the effects are not yet fully understood. Here, we hypothesised that VES mediates antitumour activity...
Autores principales: | Huang, Xiaoli, Neckenig, Markus, Sun, Jintang, Jia, Di, Dou, Yu, Ai, Dan, Nan, Zhaodi, Qu, Xun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176246/ https://www.ncbi.nlm.nih.gov/pubmed/34093795 http://dx.doi.org/10.7150/jca.52315 |
Ejemplares similares
-
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis
por: Yang, Hongcheng, et al.
Publicado: (2019) -
Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer
por: Sugimura-Nagata, Akane, et al.
Publicado: (2021) -
Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients
por: Nan, Zhaodi, et al.
Publicado: (2023) -
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
por: Al-Sudani, Hussein, et al.
Publicado: (2023) -
Registered report: The CD47-signal regulated protein alpha (SIRPa)
interaction is a therapeutic target for human solid tumors
por: Chroscinski, Denise, et al.
Publicado: (2015)